Key Highlights

  • AbCellera reported second-quarter 2026 Revenue of just $4.1 million, down 76% year on year, with a net loss of $55.4 million as it invests in its own pipeline.
  • It held about $565 million in cash and marketable securities, a substantial cushion for the pivot from licensing to owning drugs.
  • The company's future rests on internal clinical programs such as ABCL635 and ABCL575, with data readouts expected through 2026.
  • Around 35 partner-led programs remain active, with a dozen molecules in the clinic as of mid-2026, providing optional future income.

AbCellera (NASDAQ:ABCL) offers a different drug-discovery model because it began not as a maker of medicines but as a technology platform that discovers antibodies for others. Using artificial intelligence and high-throughput laboratory techniques, it identifies promising antibody candidates and has historically licensed them to pharmaceutical partners. Now, however, AbCellera is changing course, using its own engine to develop medicines it will own and advance itself.

The shares trade in the Nasdaq Composite, which includes essentially all common Equity listed on the exchange; membership follows from the listing rather than any selection on size or profitability.

A Pivot That Shows in the Numbers

The financials look, at first glance, alarming: revenue of just $4.1 million, down 76% from $17.1 million a year earlier, against research-and-development spending of $46.0 million and a net loss of $55.4 million, or $0.18 a share. But those figures reflect strategy, not distress. As AbCellera shifts from licensing discoveries to developing its own drugs, the near-term Partnership revenue that once flowed in gives way to heavy internal investment.

Crucially, it can afford to. AbCellera reported about $565 million in cash and marketable securities, and roughly $675 million of total available Liquidity including committed government funding.

The Pipeline

AbCellera's lead internal program, ABCL635, is in a Phase 2 trial, with a top-line data readout expected around August 2026. A second program, ABCL575, completed dosing in a Phase 1 study, with data expected in the fourth quarter of 2026. The company is also advancing T-cell engagers, a class of immune-directing antibodies, including through partnerships with Jazz Pharmaceuticals and Vertex. Around 35 partner-led programs remain active, with a dozen molecules in the clinic as of mid-2026.

The Opportunity

If AbCellera's internal candidates succeed, the Economics are far more attractive than the royalties it earned as a pure platform, because it keeps the upside rather than sharing it. The near-term calendar is unusually rich for a company its size, with two clinical readouts due within months.

The Economics of a Discovery Platform

A discovery platform earns a small slice of the value of each drug it helps create, a milestone here, a Royalty there, while the partner that develops and sells the medicine captures the bulk of the reward. By developing its own candidates, AbCellera is reaching for the larger share of value that comes with ownership, accepting higher risk and higher spending in exchange.

Risks

The near-term readouts could disappoint: a weak Phase 2 result for ABCL635, or poor Phase 1 data for ABCL575, would remove key sources of value. The collapse in revenue means the company is now valued on the promise of its pipeline rather than on current income, so sentiment can swing sharply on trial news.

A Discovery Engine Betting on Itself

The decisive signals are the Phase 2 readout for ABCL635 and the Phase 1 data for ABCL575, which will show whether the internal pipeline is delivering; the rate of cash burn against the $565 million balance; and any further partnerships that validate the platform. AbCellera is a genuinely different kind of biotech, a discovery engine turning itself into a drug developer, and it has the cash to see the transition through.